Join an expert panel as they discuss contemporary data related to the use of NOACs for the prevention and treatment of thromboembolic events.
Date |
Tuesday 23 June 2015 |
Event Time |
12:15 - 13:45 |
Venue |
ISTH 2015 Congress, Metro Toronto Convention Centre, 222 Bremner Blvd, Toronto, ON M5V 3L9, Canada |
Room |
717 |
Presenters:
Walter Ageno, MD
Associate Professor of Medicine,
Department of Clinical and Experimental Medicine,
University of Insubria, Varese, Italy
Mark Crowther, MD, FRCPC
Professor, McMaster University,
Hamilton, Ontario, Canada
Michael Spannagl, MD
Professor, Department of Hemostasis and Transfusion Medicine,
University of Munich, Munich, Germany
Robert P. Giugliano, MD
Senior Investigator, TIMI Study Group; Physician,
Cardiovascular Medicine, Brigham and Women's Hospital;
Associate Professor of Medicine, Harvard Medical School,
Boston, Massachusetts, United States
Target Audience
This educational activity is intended for an international audience of non-US healthcare professionals, specifically cardiologists, neurologists, internal medicine physicians, and other healthcare professionals involved in the treatment and care of patients with conditions that may require oral anticoagulant use.
Activity Overview
Join Drs Crowther, Ageno, Giugliano, and Spannagl as they discuss non-vitamin K oral antagonists (NOACs), which are now available as alternatives to warfarin and have begun to change the management of thrombus prevention and treatment in atrial fibrillation (AF), as well as how deep vein thrombosis (DVT)/pulmonary embolism (PE)are managed.
Learning Objectives
- Evaluate the strengths and limitations of NOACs in comparison to vitamin K antagonists in various patient populations based on clinical trial data, product attributes and guideline recommendations
- Recognize the pharmacokinetic differences among anticoagulant options and identify individual patient characteristics that are essential to providing safe and effective therapy, especially during emergency situations
- Clarify a management strategy for handling emergencies in patients on NOACs and keep abreast of progress in antidote development
Program Agenda
12.15 |
Welcome and Introduction |
12:20 |
Practical Challenges in Drug Selection: A Focus on New Agents |
12:47 |
Risk Stratification and Laboratory Monitoring in Emergency Situations |
13:05 |
Reversal Strategies for Bleeding Patients |
13:32 |
Question & Answer Session |
13:42 |
Concluding Remarks |
Accreditation Statement
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credits (CPD).
Supported by an independent educational grant from
